CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Public ClinicalTrials.gov record NCT03933826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of non-muscle-invasive bladder cancer (NMIBC), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with Bacillus Calmette-Guerin (BCG) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Study identification
- NCT ID
- NCT03933826
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 570 participants
Conditions and interventions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 9, 2019 (Actual)
- Primary completion
- Jan 31, 2025 (Actual)
- Completion
- Jun 30, 2029 (Estimated)
- Last update posted
- May 12, 2026
2019 – 2029
United States locations
- U.S. sites
- 36
- U.S. states
- 24
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Mayo Clinic Cancer Center | Phoenix | Arizona | 85054 | — |
| USC/Norris Comprehensive CA Center | Los Angeles | California | 90033 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | — |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| University of Miami | Miami | Florida | 33136 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| LSU Healthcare Network - Multi Specialty Clinic | Metairie | Louisiana | 70006 | — |
| Johns Hopkins University, School of Medicine | Baltimore | Maryland | 21231 | — |
| Chesapeake Urology Research Associates | Hanover | Maryland | 21076 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Michigan Medicine Rogel Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Spectrum Health | Grand Rapids | Michigan | 49503 | — |
| Comprehensive Urology -- A Division of Michigan Healthcare Professionals | Royal Oak | Michigan | 48073 | — |
| Albert Einstein College of Medicine | The Bronx | New York | 10461 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73114 | — |
| Asante Rogue Regional Medical Center | Medford | Oregon | 97504 | — |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19122 | — |
| Carolina Urologic Research Center, LLC | Myrtle Beach | South Carolina | 29572 | — |
| Urology Associates, P.C. | Nashville | Tennessee | 37209 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
| University of Washington | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03933826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 12, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03933826 live on ClinicalTrials.gov.